CONCOMITANT USE OF STRONG CYP3A4 INHIBITORS SHOULD BE AVOIDED (E.G., KETOCONAZOLE, ITRACONAZOLE, CLARITHROMYCIN, ATAZANAVIR, INDINAVIR, NEFAZODONE, NELFINAVIR, RITONAVIR, SAQUINAVIR, TELITHROMYCIN, VORICONAZOLE). GRAPEFRUIT PRODUCTS MAY ALSO INCREASE SERUM CONCENTRATIONS OF NILOTINIB AND SHOULD BE AVOIDED.
THE CONCOMITANT USE OF STRONG CYP3A4 INDUCERS SHOULD BE AVOIDED (E.G., DEXAMETHASONE, PHENYTOIN, CARBAMAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTIN, PHENOBARBITAL). PATIENTS SHOULD ALSO REFRAIN FROM TAKING ST. JOHN'S WORT. IF PATIENTS MUST BE CO-ADMINISTERED A STRONG CYP3A4 INDUCER, THE DOSE OF TASIGNA MAY NEED TO BE INCREASED,